Lymphangioleiomyomatosis — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Flavonoids of Ziziphora clinopodioides improve Alzheimer's cognitive impairment and inhibit NLRP3 inflammasome activation via autophagy-lysosome pathway.
Gu Lili et al. — Phytomedicine : international journal of phytotherapy and phytopharmacology (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41818943/
- 2.
Risdiplam Impact in Treatment Naïve and Non-Naïve Pediatric and Adult Patients With Spinal Muscular Atrophy.
Yee Pak On Patrick et al. — European journal of neurology (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41877466/
- 3.
Lipid-associated macrophages and metabolic inflammatory diseases.
Zheng Yuxiao et al. — Cell insight (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41846825/
- 4.
Hexahydroquinoline Featuring Amide Functionality: A Promising Scaffold With Calcium Channel Blocking Activity.
Koçak Aslan Ebru et al. — Drug development research (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41832946/
- 5.
Dual stimuli-responsive carriers based on pectin-coated organosilica nanoparticles for improved in planta distribution and pest control efficacy.
Abdelrahman Talat M et al. — Pesticide biochemistry and physiology (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41831910/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Recruiting — Phase 3 — Takeda
https://clinicaltrials.gov/study/NCT06722235
- 2.
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Recruiting — Phase 3 — Bristol-Myers Squibb
https://clinicaltrials.gov/study/NCT05827016
- 3.
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Recruiting — Phase 1 — Nuvalent Inc.
https://clinicaltrials.gov/study/NCT05384626
- 4.
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
Recruiting — Phase 3 — Disc Medicine, Inc
https://clinicaltrials.gov/study/NCT06910358
- 5.
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Recruiting — Phase 3 — ArriVent BioPharma, Inc.
https://clinicaltrials.gov/study/NCT07185997
- 6.
Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
Recruiting — Phase 2 — Omico
https://clinicaltrials.gov/study/NCT06003621
- 7.
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Recruiting — Phase 3 — Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
https://clinicaltrials.gov/study/NCT06615479
- 8.
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Recruiting — Phase 1 — Nested Therapeutics, Inc
https://clinicaltrials.gov/study/NCT06326411
- 9.
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Recruiting — Phase 2 — Eli Lilly and Company
https://clinicaltrials.gov/study/NCT07169851
- 10.
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting — Phase 2 — Takeda
https://clinicaltrials.gov/study/NCT06254950
- 11.
The National Australian HCV Point-of-Care Testing Program
Recruiting — Kirby Institute
https://clinicaltrials.gov/study/NCT05042544
- 12.
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Recruiting — Phase 2 — Coherus Oncology, Inc.
https://clinicaltrials.gov/study/NCT06679985
- 13.
A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Recruiting — Phase 3 — Takeda
https://clinicaltrials.gov/study/NCT06948318
- 14.
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Recruiting — Phase 2 — Takeda
https://clinicaltrials.gov/study/NCT06233461
- 15.
Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery
Recruiting — Na — Unity Health Toronto
https://clinicaltrials.gov/study/NCT04754022
- 16.
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
Recruiting — Jaeb Center for Health Research
https://clinicaltrials.gov/study/NCT05589714
- 17.
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
Recruiting — Phase 3 — GlaxoSmithKline
https://clinicaltrials.gov/study/NCT05334368
- 18.
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Recruiting — Phase 3 — Bristol-Myers Squibb
https://clinicaltrials.gov/study/NCT07116967
- 19.
ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
Recruiting — Na — Kirby Institute
https://clinicaltrials.gov/study/NCT03685045
- 20.
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Recruiting — Phase 2 — Celgene
https://clinicaltrials.gov/study/NCT03435796
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Lymphangioleiomyomatosis
Lymphangioleiomyomatosis (LAM) is a rare progressive lung disease that almost exclusively affects women, causing cystic lung destruction, breathlessness, and recurrent pneumothorax. It is caused by mutations in TSC genes. The mTOR inhibitor sirolimus slows progression and is the only approved treatment.
Most Recent Research
BACKGROUND: Ziziphora clinopodioides Lam. (Z. clinopodioides), a distinctive medicinal plant endemic to Xinjiang, is predominantly centers on cardiovascular diseases. However, its possible therapeutic value in neurologic conditions have not been thoroughly examined, especially in Alzheimer's disease (AD). PURPOSE: This study elucidates the intervention effect and mechanism of Z. clinopodioides on cognitive dysfunction in vivo and in vitro. METHODS: UPLC-Q-Exactive-HR MS/MS technology was employed to analysis the chemical components of Z. clinopodioides and that enter into the serum and brain. the extract of Z. clinopodioides and linarin were administered orally to 3 × Tg-AD mice. Behavioral assessments were carried out and AD-pathology indicator were detected. Additionally, network pharmacology and non-target metabolomics were combined to analyze the potential mechanism. RESULTS: Flavonoids from Z. clinopodioides (ZCF) were identified as the main components, with linarin being the most abundant. ZCF and linarin improved spatial memory, reduced Aβ deposition and Tau phosphorylation, and suppressed glial cell activation. Mechanistically, ZCF and linarin decreased NLRP3 protein levels and NF-κB phosphorylation, while enhancing LC3B, p62, and Cathepsin D expression, resulting in reduced IL-1β and IL-18 secretion in 3 × Tg mice, HT22 cells or BV2 cells-effects reversed by autophagy inhibition. ZCF promoted NLRP3 and p62 co-localization, leading to NLRP3 degradation via autophagy without affecting its mRNA levels. CONCLUSION: ZCF restores the autophagy-lysosome pathway and suppresses NLRP3 inflammasome activation, significantly improving cognitive dysfunction in 3 × Tg-AD mice, and highlighting ZCF or linarin as promising candidates for AD treatment.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.